TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26060395

Group type: EXPERIMENTAL
Intervention: Cream
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gauzes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dressing Gel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydrogel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Foam
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Total Symptoms Score
Number of subjects: 50
Study: 23589390

Group type: EXPERIMENTAL
Intervention: Computer-based assessment of cognitive function
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Older participants
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Participants with no current computer use
Number of subjects: 1635
Study: 21534446

Group type: EXPERIMENTAL
Intervention: Duodenal ulcer patients
Number of subjects: 175

Group type: COMPARATOR
Intervention: Gastric ulcer patients
Number of subjects: 175
Study: 20077879

Group type: EXPERIMENTAL
Intervention: Bipolar plasmakinetics vessel sealing
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard suture technique
Number of subjects: 94
Study: 16719128

Group type: EXPERIMENTAL
Intervention: Immersion baths
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no immersion baths)
Number of subjects: 108
Study: 15122540

Group type: EXPERIMENTAL
Intervention: Piribedil (150 mg mean daily dose)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 11322842

Group type: EXPERIMENTAL
Intervention: Therapeutic massage
Number of subjects: 262

Group type: COMPARATOR
Intervention: Self-care education
Number of subjects: 262

Group type: COMPARATOR
Intervention: Traditional Chinese Medical acupuncture
Number of subjects: 262
Study: 9269062

Group type: EXPERIMENTAL
Intervention: Vaccination at 0 and 24 weeks (25 U of viral antigen)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Third dose at 24 weeks
Number of subjects: 100
Study: 8323214

Group type: EXPERIMENTAL
Intervention: Wiping skin dry after 30 seconds of application of aqueous povidone-iodine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Leaving the aqueous povidone-iodine to dry
Number of subjects: 24
Study: 3087091

Group type: EXPERIMENTAL
Intervention: Clenbuterol (3 X 0.02 mg/d)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 30526610

Group type: EXPERIMENTAL
Intervention: Microbial diversity in the respiratory tract
Number of subjects: 34
Study: 27418378

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24158846

Group type: EXPERIMENTAL
Intervention: Intracameral bevacizumab (1.25 mg, 50 µL)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (balanced salt solution, 50 µL)
Number of subjects: 138
Study: 23107655

Group type: EXPERIMENTAL
Intervention: n-3PUFA (1 g/day)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 19593146

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group VIMA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (TIVA) with remifentanil and propofol (group TIVA)
Number of subjects: 26
Study: 18853563

Group type: EXPERIMENTAL
Intervention: Synaesthetic AV animations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (rotated clips, color changed clips, random AV pairings, animated clips generated by non-synaesthetes)
Number of subjects: 0
Study: 16192839

Group type: EXPERIMENTAL
Intervention: Amisulpride (AMSP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Quetiapine (QTP)
Number of subjects: 40
Study: 12625607

Group type: EXPERIMENTAL
Intervention: CS -> SVC+Can
Number of subjects: 18

Group type: COMPARATOR
Intervention: RV -> SVC+Can
Number of subjects: 18

Group type: COMPARATOR
Intervention: RV+CS -> SVC+Can
Number of subjects: 18
Study: 10476941

Group type: EXPERIMENTAL
Intervention: 5.0 IU/kg recombinant human interferon-alpha (rHuIFN-alpha)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 8759066

Group type: EXPERIMENTAL
Intervention: Plasma apo B concentrations measured at entry
Number of subjects: 2155

Group type: EXPERIMENTAL
Intervention: Plasma apo A-I concentrations measured at entry
Number of subjects: 2155

Group type: EXPERIMENTAL
Intervention: Apo B as a metabolic variable
Number of subjects: 2155
Study: 1890744

Group type: EXPERIMENTAL
Intervention: HLBI-VCAP (II) regimen (HLBI 3 x 10(6) units/day, twice a week)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HLBI-VCAP (I) regimen (HLBI 3 x 10(6) units/day, daily, 56 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: VCAP regimen only
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (VCAP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HLBI-VCAP (I) group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HLBI-VCAP (II) group
Number of subjects: 16
Study: 6356767

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment (AC)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 238
Study: 31839177

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0
Study: 30481149

Group type: EXPERIMENTAL
Intervention: Orderly displayed ECGs of limb leads
Number of subjects: 147

Group type: COMPARATOR
Intervention: Classically displayed ECGs of limb leads
Number of subjects: 147
Study: 27434611

Group type: EXPERIMENTAL
Intervention: Low-frequency treadmill training (2 times a week)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intermediate-frequency treadmill training (3 times a week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: High-frequency treadmill training (5 times a week)
Number of subjects: 30
Study: 25529384

Group type: EXPERIMENTAL
Intervention: Induction cisplatin and capecitabine (PX)
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Induction PX
Number of subjects: 706

Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 706

Group type: COMPARATOR
Intervention: Induction PF
Number of subjects: 706

Group type: COMPARATOR
Intervention: Induction sequences
Number of subjects: 706

Group type: COMPARATOR
Intervention: Adjuvant PF
Number of subjects: 706
Study: 25001306

Group type: EXPERIMENTAL
Intervention: Amodiaquine-artesunate
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 684
Study: 22885290

Group type: EXPERIMENTAL
Intervention: Dispreferred adjective orders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preferred adjective orders
Number of subjects: 0
Study: 19124057

Group type: EXPERIMENTAL
Intervention: PRP-OMPC formulations (3microg or 6microg)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: PRP-T formulation (12microg)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: All vaccine formulations
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: PRP-OMPC formulations
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: PRP-OMPC formulation with the lowest concentration
Number of subjects: 708
Study: 18590622

Group type: EXPERIMENTAL
Intervention: Telephone Mini-Mental State Examination (t‐MMSE)
Number of subjects: 141

Group type: COMPARATOR
Intervention: In-person Mini-Mental State Examination (MMSE)
Number of subjects: 141
Study: 16336480

Group type: EXPERIMENTAL
Intervention: Opioid Risk Tool (ORT)
Number of subjects: 185
Study: 12020983

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 2 mg+norethisterone acetate 1mg (E2+NETA) daily
Number of subjects: 133

Group type: COMPARATOR
Intervention: Raloxifene HCl 60 mg (Evista) daily
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 133
Study: 11783305

Group type: EXPERIMENTAL
Intervention: Juanxiao Tablet (JXT)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Oleum Vitex Negundo (Control)
Number of subjects: 447
Study: 7540461

Group type: EXPERIMENTAL
Intervention: G-CSF (5 micrograms/Kg B.W.) administered after chemotherapy cycles as needed
Number of subjects: 20
Study: 2186569

Group type: EXPERIMENTAL
Intervention: Diltiazem (Blocalcin 60, Lachema)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (Isoket retard 120, Schwarz)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 376883

Group type: EXPERIMENTAL
Intervention: Oral amphotericin B 50 mg four times a day
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 31123810

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) for 24 weeks, 90-95% peak heart rate, 2 days per week
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual care (CON)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 37
Study: 28137523

Group type: EXPERIMENTAL
Intervention: High-speed yoga
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-speed yoga
Number of subjects: 0
Study: 26343744

Group type: EXPERIMENTAL
Intervention: Debridement (CL-Deb)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Observation (CL-Obs)
Number of subjects: 190
Study: 23433395

Group type: EXPERIMENTAL
Intervention: Standard government school feeding programme
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Home-grown school feeding and social accountability programme
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 116
Study: 21251363

Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM) group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-Recruitment Maneuver (non-RM) group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 19038583

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17205440

Group type: EXPERIMENTAL
Intervention: Miltefosine, 2.5 mg/kg/day for 28 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Amphotericin B, 45 mg/kg over 90 days
Number of subjects: 72
Study: 15622126

Group type: EXPERIMENTAL
Intervention: LF-ASD brain switch
Number of subjects: 2
Study: 11338008

Group type: EXPERIMENTAL
Intervention: Minimally invasive cardiac surgery (MICS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional cardiac surgery
Number of subjects: 48
Study: 9376698

Group type: EXPERIMENTAL
Intervention: E153
Number of subjects: 74

Group type: COMPARATOR
Intervention: Alcon BSS
Number of subjects: 74

Group type: COMPARATOR
Intervention: Alcon BSS Plus
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 74
Study: 7890461

Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) group (n = 16) received 80% of their habitual energy intake for ten weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) group (n = 16)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n = 8) received weight-maintaining diet for ten weeks
Number of subjects: 24
Study: 3065355

Group type: EXPERIMENTAL
Intervention: 150 mg of mifepristone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 450 mg of mifepristone
Number of subjects: 35
Study: 29136682

Group type: EXPERIMENTAL
Intervention: CCC Workshop
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 84
Study: 28877312

Group type: EXPERIMENTAL
Intervention: Topical fluorouracil, 5%, cream applied twice daily for 2 to 4 weeks (28 to 56 doses)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Vehicle control cream applied twice daily for 2 to 4 weeks (28 to 56 doses)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Topical fluorouracil, 5%, cream
Number of subjects: 281

Group type: COMPARATOR
Intervention: Vehicle control cream
Number of subjects: 281
Study: 26598079

Group type: EXPERIMENTAL
Intervention: Carbon dioxide contrast medium
Number of subjects: 21

Group type: COMPARATOR
Intervention: Iodine contrast medium
Number of subjects: 21
Study: 23578589

Group type: EXPERIMENTAL
Intervention: Selling cigarettes (loosies)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Providing street security
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Selling food stamps
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Pawning items
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Selling drugs
Number of subjects: 801
Study: 21149743

Group type: EXPERIMENTAL
Intervention: Electronic messages highlighting overdue screening status with a link to a Web-based risk assessment tool.
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Electronic messages highlighting overdue screening status with a link to a Web-based risk assessment tool (among those who viewed the message).
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Risk assessment tool users.
Number of subjects: 1103
Study: 18665117

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study: 16788295

Group type: EXPERIMENTAL
Intervention: Activity Index (AI(ADL))
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Barthel Index (BI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Barthel Index (BI) and Activity Index (AI(ADL))
Number of subjects: 75
Study: 12897732

Group type: EXPERIMENTAL
Intervention: Hormone therapy (estrogens, progestins, and their combination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11350672

Group type: EXPERIMENTAL
Intervention: Damp gauze (Group G)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Large‐tip cotton buds (Group C)
Number of subjects: 10
Study: 9411409

Group type: COMPARATOR
Intervention: Impaired LV filling parameters (MV E/A 0.81 +/- 0.12)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Abnormal mitral flow parameters (MV E/A 0.72 +/- 0.15)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Abnormal tricuspid flow parameters (TV E/A 0.8 +/- 0.19)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Impaired diastolic filling of both ventricles (MV E/A 0.72 +/- 0.15)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Correlation between TV A and MV E
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Correlation between MV E-VTI
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Correlation between MV A
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Correlation between LV mass and TV E
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Correlation between time velocity integral of early tricuspid inflow
Number of subjects: 74
Study: 1305312

Group type: EXPERIMENTAL
Intervention: Etodolac 300 mg b.i.d.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Piroxicam 20 mg/day plus placebo
Number of subjects: 61
Study: 3906106

Group type: EXPERIMENTAL
Intervention: Progesterone treatment (100 mg twice daily delivered in vaginal pessaries)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15
Study: 31647280

Group type: EXPERIMENTAL
Intervention: 40 IU intranasal insulin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29454255

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 26855018

Group type: EXPERIMENTAL
Intervention: Liraglutide (glucagon‐like peptide‐1 receptor agonist)
Number of subjects: 9340

Group type: EXPERIMENTAL
Intervention: Prior CVD
Number of subjects: 9340

Group type: EXPERIMENTAL
Intervention: Residency in North America
Number of subjects: 9340
Study: 24356862

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring-based dose adaptation strategy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 41
Study: 21851293

Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy (modified CIMT) at home (n=7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Modified constraint-induced movement therapy (modified CIMT) at clinic (n=7)
Number of subjects: 14
Study: 20417856

Group type: EXPERIMENTAL
Intervention: 1.8 mg liraglutide
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: 1.2 mg liraglutide
Number of subjects: 665

Group type: COMPARATOR
Intervention: Sitagliptin (100 mg)
Number of subjects: 665

Group type: COMPARATOR
Intervention: 1.8 mg liraglutide vs Sitagliptin
Number of subjects: 665

Group type: COMPARATOR
Intervention: 1.2 mg liraglutide vs Sitagliptin
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Liraglutide (both doses)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 665
Study: 18500610

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0 MAC)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Isoflurane (1.0 MAC)
Number of subjects: 44
Study: 15694949

Group type: EXPERIMENTAL
Intervention: Fluvastatin, 40 mg daily
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (physical activity and diet)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 568
Study: 12672708

Group type: EXPERIMENTAL
Intervention: Whole tablet dietary supplement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Crushed tablet dietary supplement
Number of subjects: 15

Group type: COMPARATOR
Intervention: Test meal alone (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intestinal permeability influence on vitamin B(12)
Number of subjects: 15
Study: 10881002

Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) 25 mg/m(2), i.v., weekly, x4 (cumulative dose 100 mg/m(2))
Number of subjects: 90

Group type: COMPARATOR
Intervention: No daunorubicin (DNR)
Number of subjects: 90
Study: 8567951

Group type: EXPERIMENTAL
Intervention: Pattern of viral replication (rapid increase in plasma viral RNA and cell-associated proviral DNA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pattern of viral replication (initial rapid increase followed by a decline in viral levels)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pattern of viral replication (significantly lower viral increase)
Number of subjects: 11
Study: 1571905

Group type: EXPERIMENTAL
Intervention: Accelerated superfractionated radiation therapy using a concomitant boost twice‐a‐day schedule (BID); 180 cGy/fraction with a boost of 160 cGy/fraction BID, 3 days per week.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional once‐a‐day (QD) fractionation to doses in excess of 6600 cGy.
Number of subjects: 100
Study: 6363727

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide
Number of subjects: 668

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 668
Study: 30401610

Group type: EXPERIMENTAL
Intervention: 24,000 IU vitamin D3/mo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 60,000 IU vitamin D3/mo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 24,000 IU vitamin D3 plus 300 μg calcifediol/mo
Number of subjects: 200
Study: 29414988

Group type: EXPERIMENTAL
Intervention: Crossover feet (XF)
Number of subjects: 27
Study: 27009179

Group type: EXPERIMENTAL
Intervention: Spatially targeted vaccination (80% of adults in hotspots)
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Untargeted vaccination (8% of adults in general population)
Number of subjects: 100000
Study: 25257928

Group type: EXPERIMENTAL
Intervention: Early External Cephalic Version (EECV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed External Cephalic Version (EECV)
Number of subjects: 0
Study: 22512265

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glibenclamide (5 mg/day)
Number of subjects: 40
Study: 20615746

Group type: EXPERIMENTAL
Intervention: Perceived neighborhood characteristics (children do not play outdoors, neighborhood well lit, presence of trails)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neighborhood or transportation measures
Number of subjects: 0
Study: 18042032

Group type: COMPARATOR
Intervention: 10 mL of 2% lidocaine gel intrarectally 10 minutes before biopsy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 10 mL of intrarectal 40% DMSO with lidocaine equal to that in the lidocaine gel 10 minutes before procedure
Number of subjects: 62
Study: 11213851

Group type: EXPERIMENTAL
Intervention: Lamotrigine chewable dispersible tablets administered rectally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lamotrigine chewable dispersible tablets administered orally
Number of subjects: 12
Study: 9278079

Group type: EXPERIMENTAL
Intervention: AO 3.5‐millimeter cannulated screw
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Acutrak cannulated screw
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Herbert‐Whipple screw
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Universal Compression screw
Number of subjects: 2

Group type: COMPARATOR
Intervention: Herbert screw
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: AO screw and Herbert screw (in a separate setup)
Number of subjects: 2
Study: 8101813

Group type: EXPERIMENTAL
Intervention: Buserelin (20 micrograms, nasal spray, daily for 28 days)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Buserelin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 59
Study: 3461193

Group type: EXPERIMENTAL
Intervention: Breast cancer screening
Number of subjects: 0
Study: 29441424

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Non-users of SSRIs
Number of subjects: 1138
Study: 27501953

Group type: EXPERIMENTAL
Intervention: Flapless (FLS) immediate implant placement
Number of subjects: 39

Group type: COMPARATOR
Intervention: Flap-involving (F) immediate implant placement
Number of subjects: 39
Study: 24334800

Group type: EXPERIMENTAL
Intervention: PIVC inserted in hand, antecubital fossa, or upper arm
Number of subjects: 3283

Group type: EXPERIMENTAL
Intervention: Larger diameter PIVC
Number of subjects: 3283

Group type: EXPERIMENTAL
Intervention: PIVC inserted by operating and radiology suite staff
Number of subjects: 3283

Group type: EXPERIMENTAL
Intervention: PIVC inserted in hand or antecubital fossa
Number of subjects: 3283

Group type: EXPERIMENTAL
Intervention: Clinical staff insertion
Number of subjects: 3283

Group type: EXPERIMENTAL
Intervention: Smaller PIVC diameter
Number of subjects: 3283

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 3283